ONLINE EXPERT POSTER REVIEW AND DISCUSSION

REPORTING FROM

The 47th Annual Meeting of the European Association for the Study of the Liver (EASL)

JOINTLY SPONSORED BY THE POSTGRADUATE INSTITUTE FOR MEDICINE AND VIRALED, LLC.

Dual Oral Therapy with the NS5A Inhibitor (BMS-790052) and NS3 PI (BMS-650032) in HCV Genotype 1B-Infected Null Responder or Ineligible/Intolerant to Peginterferon/Ribavirin

F. Suzuki, K. Ikeda, J. Toyota, Y. Karino2, T. Ohmur, K. Chayama, S. Takahashi, Y. Kawakami, H. Ishikawa, H. Watanabe, W. Hu, F. McPhee, E. Hughes, H. Kumada

Abstract #14

Open-Label Phase 2a Study (AI447-017)

Null responders (N = 21)

DCV 60 mg QD + ASV 200 mg BID*	Follow-up x 24 weeks

Ineligible/intolerant (N = 22)

DCV 60 mg QD + ASV 200 mg BID	Follow-up x 24 weeks

Week 4 (RVR)	Week 12 (cEVR)	Week 24 (EOTR)	Post-treatment Week 12 (SVR_{12})	Post-treatment Week 24 (SVR_{24})

- Non-cirrhotic Japanese adults with HCV genotype 1 infection, HCV RNA ≥ 105 IU/mL
  - Null responders: < 2 log10 HCV RNA decline after ≥ 12 weeks of peg-alfa/RBV
  - Ineligible/intolerant: previously intolerant to peg-alfa/RBV OR peg-alfa/RBV medically unsuitable
- Sentinel cohort of 10 null responders reported previously (SVR24 90%); 1 results combined here with data for additional null responders
- Primary efficacy endpoint: SVR12

*ASV initially 600 mg BID in sentinel cohort of 10 null responders, reduced to 200 mg BID during treatment

cEVR, complete early virologic response; EOTR, end of treatment response; eRVR, extended rapid virologic response; RVR, rapid virologic response; SVR sustained virologic response

1Chayama K, et al. Hepatology 2012; 55:742-748.
Suzuki F et al. 47th EASL; Barcelona, Spain; April 18-22, 2012. Abst. 14.

Undetectable HCV RNA By Patient Group



a End of treatment = Week 24 or last on-treatment visit for patients who discontinued early Intention to treat (missing = failure) analysis

Suzuki F et al. 47th EASL; Barcelona, Spain; April 18-22, 2012. Abst. 14.

Study A1444-040



Sulkowski M et al. 47th EASL; Barcelona, Spain; April 18-22, 2012. Abst. 1422.

Virologic Response During and After Treatment (mITT)



mITT analysis, bars not reaching 100% after week 4 reflect missing values.
PT = posttreatment

Sulkowski M et al. 47th EASL; Barcelona, Spain; April 18-22, 2012. Abst. 1422.

HCV Genotype 2/3



mITT analysis, bars not reaching 100% after week 4 reflect missing values.
1 patient required addition of peg-alfa/RBV (treatment intensificaiton), 1 patient with relapse at posttreatment Week 4.
2 patients lost to follow-up (following Week 12 and 24 visits).

Sulkowski M et al. 47th EASL; Barcelona, Spain; April 18-22, 2012. Abst. 1422.